Literature DB >> 31358498

Altered ellipsoid zone reflectivity and deep capillary plexus rarefaction correlate with progression in Best disease.

Francesco Romano1,2, Alessandro Arrigo3, Pier Pasquale Leone4, Andrea Saladino5, Francesco Bandello5, Maurizio Battaglia Parodi5.   

Abstract

AIMS: To evaluate the effects of neurovascular damage in patients with the typical vitelliform lesion of Best vitelliform macular dystrophy (BVMD) in the attempt to identify different progression patterns.
METHODS: Prospective, observational case series. Patients in the vitelliform stage of BVMD and healthy controls underwent complete ophthalmological examination on a yearly basis, including best-corrected visual acuity (BCVA), biomicroscopy, optical coherence tomography (OCT) and OCT angiography (OCT-A). 4.5×4.5 mm OCT-A slabs were imported into ImageJ software and their vessel density (VD) was calculated. Similarly, the ellipsoid zone (EZ) was manually outlined and the reflectivity was measured above the vitelliform lesion and in the 500 µm external to it. Retinal pigment epithelium-Bruch's membrane complex was taken as internal reference.
RESULTS: 34 eyes (24 patients) and 34 matched controls were included in the study. Mean follow-up was of 28.4±5.8 months, with 12 eyes showing signs of stage progression at the end follow-up. The EZ overlying the vitelliform lesion and in the peri-lesional area disclosed a significant reduction in reflectivity when compared with the foveal and para-foveal EZ of controls, respectively. VD resulted meaningfully decreased only at the deep capillary plexus. Of notice, more extensive EZ (reflectivity <0.7) and vascular alterations (VD <0.4) at baseline strongly correlated with worse BCVA and were associated with a more rapid progression at follow-up.
CONCLUSIONS: Both EZ reflectivity and VD at deep capillary plexus may prove valuable biomarkers to assess BVMD severity and detect progression. In this view, 'rapid progressors' might benefit the most from timely genetic therapies in the future. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Best disease; OCT-A; ellipsoid zone; neurovascular damage; progression biomarkers; vessel density

Year:  2019        PMID: 31358498     DOI: 10.1136/bjophthalmol-2019-313980

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

Review 1.  The role of multimodal imaging and vision function testing in ABCA4-related retinopathies and their relevance to future therapeutic interventions.

Authors:  Saoud Al-Khuzaei; Mital Shah; Charlotte R Foster; Jing Yu; Suzanne Broadgate; Stephanie Halford; Susan M Downes
Journal:  Ther Adv Ophthalmol       Date:  2021-12-19

2.  Retinal vascular impairment in Wolfram syndrome: an optical coherence tomography angiography study.

Authors:  Marco Battista; Maria Lucia Cascavilla; Domenico Grosso; Enrico Borrelli; Giulio Frontino; Giulia Amore; Michele Carbonelli; Riccardo Bonfanti; Andrea Rigamonti; Costanza Barresi; Chiara Viganò; Beatrice Tombolini; Anna Crepaldi; Marina Montemagni; Chiara La Morgia; Francesco Bandello; Piero Barboni
Journal:  Sci Rep       Date:  2022-02-08       Impact factor: 4.379

Review 3.  Artificial intelligence extension of the OSCAR-IB criteria.

Authors:  Axel Petzold; Philipp Albrecht; Laura Balcer; Erik Bekkers; Alexander U Brandt; Peter A Calabresi; Orla Galvin Deborah; Jennifer S Graves; Ari Green; Pearse A Keane; Jenny A Nij Bijvank; Josemir W Sander; Friedemann Paul; Shiv Saidha; Pablo Villoslada; Siegfried K Wagner; E Ann Yeh
Journal:  Ann Clin Transl Neurol       Date:  2021-05-19       Impact factor: 4.511

4.  Optical coherence tomography features of the repair tissue following RPE tear and their correlation with visual outcomes.

Authors:  Francesco Romano; Salvatore Parrulli; Maurizio Battaglia Parodi; Marco Lupidi; Matteo Cereda; Giovanni Staurenghi; Alessandro Invernizzi
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.